ACP
SLRN

Acuta Capital Partners’s ACELYRIN SLRN Stock Holding History

Acuta Capital Partners’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-364,000
Closed -$1.79M – 47
2024
Q3 		$1.79M Buy
+364,000
New +$1.88M 1.45% 21

Other funds holding SLRN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Acuta Capital Partners's SLRN Position: Q4 2024 in Review

Acuta Capital Partners sold out of ACELYRIN (SLRN) in Q4 2024, closing a stake of 364,000 shares — an estimated $1.79M sold.

Acuta Capital Partners first reported a position in SLRN in Q3 2024 and held it in 1 quarter. The position peaked at $1.79M in Q3 2024. 125 funds tracked by Wall St. Rank hold SLRN as of Q4 2024.

  • Acuta Capital Partners reported no remaining ACELYRIN position as of Q4 2024 after selling out during the quarter.
  • Acuta Capital Partners sold 364,000 ACELYRIN shares in Q4 2024, an estimated $1.79M.
  • Acuta Capital Partners first reported a position in ACELYRIN in Q3 2024 and held it in 1 quarter.
  • Acuta Capital Partners's ACELYRIN position peaked at $1.79M in Q3 2024.
  • 125 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2024.

Based on Acuta Capital Partners's 13F filing for Q4 2024, filed 14 Feb 2025.